Identifying former injecting drug users infected with hepatitis C: An evaluation of a general practice-based case-finding intervention

Journal of Public Health

Volumn 34, Issue 1, 2012, Pages 14-23

  Cullen, B L ^a   Hutchinson, S J ^a,b   Cameron, S O ^c   Anderson, E ^d   Ahmed, S ^d   Spence, E ^c   Mills, P R ^c   Mandeville, R ^e   Forrest, E ^f   Washington, M ^g   Wong, R ^c   Fox, R ^c   Goldberg, D J ^a  

^a HEALTH PROTECTION SCOTLAND   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^d NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^e Keppoch Medical Practice   (United Kingdom)

^f GLASGOW ROYAL INFIRMARY   (United Kingdom)

^g NONE   (United Kingdom)

Author keywords

epidemiology; primary care; screening

Indexed keywords

EID: 84857530408     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/pubmed/fdr097     Document Type: Article

References (36)

1. World Health Organisation. Hepatitis C Fact Sheet (revised October 2000). http://www.who.int/mediacentre/factsheets/fs164/en/index.html (28 November 2007, date last accessed).
2. Scottish Government. Hepatitis C Action Plan for Scotland. Phase II: May 2008-March 2011. Edinburgh: St. Andrew's House, 2008. http://www.scotland.gov. uk/Resource/Doc/222750/0059978.pdf (8 August 2008, date last accessed).
3. Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, CDSC Northern Ireland, and the CRDHB. Shooting Up: Infections among Injecting Drug Users in the United Kingdom 2006. London: Health Protection Agency, 2007.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82.
5. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65.
6. Freeman AJ, Gore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34(4 Pt 1):809-16.
7. National Institute for Health and Clinical Excellence. Peginterferon Alfa and Ribavirin for the Treatment of Mild Chronic Hepatitis C. London: NICE, 2006. http://www.nice.org.uk/nicemedia/pdf/TA106guidance.pdf (8 August 2008, date last accessed).
8. Scottish Intercollegiate Guidelines Network. Management of Hepatitis C: A National Clinical Guideline. Edinburgh: NHS Quality Improvement Scotland, 2006.
9. Hutchinson SJ, Roy KM, Wadd S Hepatitis C virus infection in Scotland: epidemiological review and public health challenges. Scott Med J 2006;51:8-13.
10. Consensus Conference on Hepatitis C. Final Consensus Statement. Edinburgh: Royal College of Physicians of Edinburgh, 2004.
11. Anderson EA, Mandeville R, Hutchinson SJ et al. Evaluation of a general practice based Hepatitis C virus screening intervention. Scott Med J 2009;54(3):3-7.
12. Castelnuovo E, Thompson-Coon J, Pitt M et al. The costeffectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 2006;10(32):iii-xii. , 1.
13. Thompson Coon J, Castelnuovo E, Pitt M et al. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract 2006;23(4):393-406.
14. Carstairs V, Morris R. Deprivation and Health in Scotland. Aberdeen: Aberdeen University Press, 1991.
15. McLoone P. Carstairs Scores for Scottish Postcode Sectors from the 2001 Census. Glasgow: Medical Research Council Social and Public Health Sciences Unit, 2004.
16. Shaw L, Taylor A, Roy KM et al. Establishment of a database of a diagnosed HCV-infected persons in Scotland. Commun Dis Public Health 2003;6:305-10.
17. Taylor A, Allen E, Hutchinson S et al. Evaluation of the Lord Advocates Guidance on the Distribution of Sterile Needles and Syringes to Injecting Drug Users. Scottish Executive Effective Interventions Unit, 2005. www. drugmisuse.isdscotland.org/eiu/pubs/eiu-097.htm.
18. Hutchinson SJ, Goldberg DJ, King M et al. Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation and diagnosis. Gut 2004;53:593-8. (Pubitemid 38372987)
19. Goldberg D, Cameron S, Sharp G et al. Hepatitis C virus among genitourinary clinic attenders in Scotland: unlinked anonymous testing. Int J STD AIDS 2001;12:17-21. (Pubitemid 32113006)
20. Statistical Package for Social Scientists (SPSS). SPSS Base 14.0 User's Guide. SPSS Inc., 2005. ISBN 0-13-221804-6.
21. Miles M, Huberman A. Qualitative Data Analysis. London: Sage, 1984.
22. Burgess RG. Field Research: A Sourcebook and Field Manual. London: Allen & Unwin, 1982.
23. Information Services Division (NHS National Services Scotland). Practice populations by deprivation status (as at 30 September 2007). http://www.isdscotland.org/isd/files/GPWF-Jan08-Deprivation-CHI07-lookup06.xls (12 November 2006, date last accessed).
24. Scottish Government. Scottish Index of Multiple Deprivation. Edinburgh: St. Andrew's House, 2006.
25. Altman C, Lesiour A, Dunbavand A et al. Depistage des malades a risque d'infection virale C en Medecine generale. Gastroenterol Clin Biol 1999;23:359-62.
26. Roudot-Thoraval F, Monnet E, Mercet P et al. Strategies of hepatitis C screening in general practice. Results of a two centre randomised trial. Gastroenterol Clin Biol 2000;24:1037-41. (Pubitemid 32002945)
27. Pradat P, Caillet-Vallet E, Sahajian F et al. Prevalence of hepatitis C infection among general practice patients in the Lyon area, France. Eur J Epidemiol 2001;17:47-51. (Pubitemid 32756591)
28. Josset V, Torre JP, Tavolacci MP et al. Efficiency of hepatitis C virus screening strategies in general practice. Gastroenterol Clin Biol 2004;28:351-7. (Pubitemid 38691089)
29. Monnet E, Mercet P, Woronoff-Lemsi M-C et al. Organized hepatitis C screening. Results and cost of a one-year campaign in a French pilot area. Gastroenterol Clin Biol 2000;24:541-6. (Pubitemid 30489382)
30. Cullen W, Stanley J, Langton D et al. Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation. Br J Gen Pract 2006;56(532):848-56.
31. Judd A, Parry J, Hickman M et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol 2003;71(1):49-55. (Pubitemid 37121912)
32. Hickman M, McDonald T, Judd A et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat 2008;15(4):250-4. (Pubitemid 351326904)
33. Jack K, Willott S, Manners J et al. Clinical trial: a primary-care based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther 2009;29(1):38-45.
34. Cullen W, Bury G, Barry J et al. Hepatitis C infection among drug users attending general practice. Ir J Med Sci 2003;172: 123-7. (Pubitemid 37493488)
35. Hutchinson S, Bird S, Goldberg D. Modelling the current and future disease burden of Hepatitis C among injecting drug users in Scotland. Hepatology 2005;42:711-23.
36. Martin N, Vickerman P, Foster GR et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modelling analysis of its prevention utility. J Hepatol 2011;54:1137-44.